Kalamazoo Resources Ltd
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 58
- Market Cap
- $46.4M
- Introduction
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE)
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT05781750
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸Southwest Kidney Institute, Surprise, Arizona, United States
🇺🇸Valerius Medical Group and Research Center of Greater Long Beach, Inc., Los Alamitos, California, United States
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
- Conditions
- Autoimmune Hepatitis
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05569759
- Locations
- 🇺🇸
Northwell Health Center for Liver Disease and Transplantation, Manhasset, New York, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
KZR-261 in Subjects With Advanced Solid Malignancies
- Conditions
- Advanced/Metastatic Solid Tumor
- Interventions
- Drug: KZR-261
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05047536
- Locations
- 🇺🇸
START (South Texas Accelerated Research Therapeutics), San Antonio, Texas, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville, Nashville, Tennessee, United States
Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
- Conditions
- PolymyositisDermatomyositis
- Interventions
- Drug: KZR-616
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04628936
- Locations
- 🇨🇿
KZR Research Site, Prague, Czechia
A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
- Conditions
- Immune ThrombocytopeniaAutoimmune Hemolytic Anemia
- Interventions
- Drug: KZR-616
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Registration Number
- NCT04039477
- Locations
- 🇺🇸
KZR-616 Research Site, Rochester, Minnesota, United States
🇷🇺KZR Research Site, Saint Petersburg, Russian Federation
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
- Conditions
- PolymyositisDermatomyositis
- Interventions
- Drug: KZR-616Drug: Placebo
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04033926
- Locations
- 🇩🇪
KZR Research Site, Göttingen, Germany
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
- Conditions
- Systemic Lupus ErythematosusLupus Nephritis
- Interventions
- Drug: KZR-616
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Kezar Life Sciences, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT03393013
- Locations
- 🇺🇸
Hope Clinical Trials, Inc., Miami, Florida, United States
🇦🇺Monash Health, Clayton, Victoria, Australia
🇦🇺The Royal Melbourne Hospital, Parkville, Victoria, Australia